Inflammation and auto-immune disorders therapeutic - Galapagos NV
Alternative Names: pBIC-assetsLatest Information Update: 09 Jan 2026
At a glance
- Originator Galapagos NV
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Inflammation
Most Recent Events
- 18 Sep 2025 Early research in Autoimmune disorders in Belgium (unspecified route), prior to September 2025 (Galapagos NV pipeline, September 2025)
- 18 Sep 2025 Early research in Inflammation in Belgium (unspecified route), prior to September 2025 (Galapagos NV pipeline, September 2025)